1Q12 Non-GAAP Adjusted Net Income was RMB1.4 Million ($0.2 Million)
Live conference call to be held Thursday, May 24, 2012 at 8:00 am ET
BEIJING, May 23, 2012 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced unaudited financial results for the first quarter of 2012.
Mr. Baizhong Xue, the Company's Chairman and Chief Executive Officer, stated, "We are pleased to announce financial results for the first quarter of 2012 which demonstrate that Nuokang has been gradually recovering through our restructuring efforts. This quarter, revenue from our flagship Baquting product recovered sequentially to RMB57.5 million from RMB52.2 million in the fourth quarter of 2011. Our marketing agent sales remained strong. Our direct sales, although weak compared to the prior year period, recovered noticeably from the fourth quarter of 2011. This is especially significant in light of the first quarter historically being our seasonally weaker period as it coincides with the Chinese New Year. We are encouraged by these positive signs and continue to believe in the potential of our product portfolio.
"We continue to focus on strengthening our business through several measures. First, we continue to adjust our sales strategy for Baquting to better adapt to an increasingly competitive landscape. Next, we are diversifying our product portfolio by investing in market education and clinical trials for new products to generate greater recognition for their efficacy and safety. Lastly, we will maintain a strong balance sheet and operating cash flows. Looking ahead, we anticipate gradual recovery in revenue and profit."
First Quarter 2012 Financial Highlights
Revenue was RMB60.3 million ($9.6 million)1 compared to RMB64.5 million in the prior year period;
Baquting revenue was RMB57.5 million ($9.1 million) compared to RMB60.8 million in the prior year period;
Gross profit was RMB52.1 million ($8.3 million) compared to RMB56.3 million in the prior year period;
Gross margin was 86.5% compared to 87.2% in the prior year period;
Operating income was RMB747,000 ($119,000) compared to RMB17.9 million in the prior year period;
Net income was RMB700,000 ($111,000), or RMB0.04 ($0.01) per diluted ADS2 compared to RMB10.9 million, or RMB0.55 per diluted ADS, in the prior year period; and
Non-GAAP adjusted net income was RMB1.4 million ($216,000) compared to RMB13.8 million in the prior year period.
First Quarter 2012 Financial Performance
Revenue for the first quarter of 2012 was RMB60.3 million ($9.6 million) compared to RMB64.5 million in the first quarter of 2011. Revenue from Baquting decreased to RMB57.5 million ($9.1 million) from RMB60.8 million in the prior year period but increased sequentially from RMB52.2 million in the fourth quarter of 2011. This sequential growth reflects the gradual stabilization of the Company's sales team structure and performance. Baquting revenue as a percentage of total revenue was 95.4% in the first quarter of 2012 compared to 94.2% in first quarter of 2011. Revenue from other products was RMB2.7 million ($0.4 million) compared to RMB3.8 million in the prior year period.
Gross profit for the first quarter of 2012 was RMB52.1 million ($8.3 million) compared to RMB56.3 million in the first quarter of 2011. Gross margin was 86.5% compared to 87.2% in the first quarter of 2011. This margin recovery reflects the nascent recovery of the Company's direct sales team's performance as well as the continued strong performance of its marketing agent sales.
Operating income was RMB747,000 ($119,000) compared to RMB17.9 million in the prior year period. This continues to reflect the Company's focus on strengthening its sales and marketing team for both Baquting and the Company's new products throughout the first quarter of 2012.
Research and development expenses were RMB2.7 million ($0.4 million) compared to RMB4.2 million in the prior year period. Research and development expenses as a percentage of revenue was 4.5%, within the Company's expected range.
Selling, marketing and distribution expenses increased 69.2% to RMB35.8 million ($5.7 million) from RMB21.2 million in the prior year period. This was primarily due to the Company's investment in sales and marketing for Baquting in the first quarter of 2012 to combat similar increases in marketing activities by industry peers as well as the Company's continued investment in the commercialization of Kaitong and Alpha Lipoic Acid Capsule. Sales, marketing and distribution expense ratio for the first quarter of 2012 was sequentially lower. The Company expects this ratio will continue to decrease as revenues from new products ramp up.
General and administrative expenses remained steady and in line with the Company's expected range at RMB12.9 million ($2.0 million) from the prior year period.
Provision for income taxes was RMB358,000 ($57,000) compared to RMB4.6 million in the prior year period, as a result of decreased income before tax.
Net income was RMB700,000 ($111,000), or RMB0.04 ($0.01) per diluted ADS compared to RMB10.9 million, or RMB0.55 per diluted ADS, in the prior year period.
Non-GAAP adjusted net income, excluding share-based compensation, foreign exchange gains and losses and FIN 48 adjustment, was RMB1.4 million ($216,000) compared to RMB13.8 million in the prior year period.
For the quarter ended March 31, 2012, the Company had approximately 154.8 million weighted average diluted ordinary shares outstanding, or 19.4 million weighted average diluted ADSs.
As of March 31, 2012, the Company had cash and cash equivalents and other short-term investments of RMB231.9 million ($36.8 million) compared to RMB179.4 million as of December 31, 2011.
New Product Performance
The Company continued to make progress with market education and sales channel development for Kaitong and Alpha Lipoic Acid Capsule ("ALA"). For Kaitong, the Company has recently won bids for two additional provinces, bringing the total to ten provinces and four military zones.
For Dianatal® and the new cardiovascular product, the Company is awaiting final-stage SFDA review of testing results. The Company expects SFDA approval by the end of 2012 for both products.
Adjusted net income is presented to better illustrate the Company's ongoing and core operational results. Adjusted net income is defined as net income excluding share-based compensation expense, foreign exchange losses, and FIN 48 adjustment. Adjusted net income may be calculated differently, and therefore Nuokang's adjusted net income may not be comparable to similarly titled measures of other companies. Adjusted net income is not a measure of financial performance under U.S. generally accepted accounting principles (GAAP), and should not be considered in isolation or as an alternative to net income, cash flows from operating activities and other measures determined in accordance with GAAP. Items excluded from adjusted net income are significant and necessary components to the operations of the Company's business, and, therefore, adjusted net income should only be used as a supplemental measure of operating performance.
The Company will hold a conference call at 8:00 a.m. ET on Thursday, May 24, 2012 to discuss the first quarter 2012 financial results. Listeners may access the call by dialing:
United States toll free:
China toll free:
Hong Kong toll free:
United Kingdom toll free:
A telephone replay will become available beginning two hours after the conclusion of the call and will remain available through June 7, 2012. Listeners may access the replay by dialing:
United States toll free:
A webcast will also be available through the Company's website www.nkbp.com.
About China Nuokang Bio-Pharmaceutical Inc.
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hospital-based medical products. The Company provides a diversified portfolio of products across more than 4,200 hospitals in China. Nuokang's principal products include Baquting®, China's leading hemocoagulase product by market share, Kaitong®, a lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis; and alpha lipoic acid capsules, or ALA, an antioxidant product that addresses diabetic neuropathy. The Company's product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. Please visit www.nkbp.com for more information.
This press release contains statements of a forward-looking nature. These statements, including the management quotations and the statements relating to the Company's new product development, are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals, and projections, which are subject to numerous assumptions, risks, and uncertainties. These forward-looking statements may include, but are not limited to, statements containing words such as "may," "could," "would," "plan," "anticipate," "believe," "estimate," "predict," "potential," "expects," "intends" and "future" or similar expressions. Among other things, the statements relating to the Company's expected progress on the product portfolio and future financial results may contain forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to change at any time. These forward-looking statements are based upon management's current expectations and are subject to a number of risks, uncertainties and contingencies, many of which are beyond the Company's control that may cause actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. The Company's actual results could differ materially from those contained in the forward-looking statements due to a number of factors, including those described under the heading "Risk Factors" in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F.
1 This announcement contains translations of certain Renminbi amounts into US dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to US dollars as of and for the quarter ended March 31, 2012, were made at the noon buying rate of RMB6.2975 to USD1.00 on March 30, 2012 in the City of New York for cable transfers in Renminbi per US dollar as certified for customs purposes by the Federal Reserve Bank of New York. China Nuokang Bio-Pharmaceutical Inc. makes no representation that the Renminbi or US dollar amounts referred to in this press release could have been or could be converted into US dollars or Renminbi, at any particular rate or at all.
2 The Company's American Depositary Shares, which are traded on the NASDAQ, each of which represents eight ordinary shares of the Company.
CONSOLIDATED STATEMENTS OF INCOME
FOR THE QUARTERS ENDED MARCH 31, 2011 AND 2012
Cost of revenue
Research and development costs
Selling, marketing and distribution expenses
General and administrative expenses
Total operating expenses
Foreign exchange (losses) gain
Other (loss) income, net
Income before income tax expense
Income tax expense
Net loss attributable to non-controlling interest
Net income attributed to ordinary shares
Net income per share
Shares used in net income pershare computation
Net income per ADS
Shares used in net income per ADS computation
CONSOLIDATED BALANCE SHEETS
AS OF DECEMBER 31, 2011 and MARCH 31, 2012
Cash and cash equivalents
Accounts receivable (net of allowance for doubtful accounts of RMB394 and RMB394 (US$63) as of December 31, 2011 and March 31, 2012, respectively)
Prepaid income tax
Deferred tax assets
Total current assets
Property, plant and equipment, net
Land use rights, net
Intangible assets, net
Deferred tax assets
Total non-current assets
LIABILITIES AND SHAREHOLDERS' EQUITY
Short-term bank loans
Accrued expenses and other payables
Income tax payable
Unrecognized tax benefits
Total current liabilities
Deferred tax liabilities
Deferred government grants
Total non-current liabilities
Commitments and contingencies
Ordinary shares (par value US$0.0005 per share, 474,200,000 shares authorized and 157,906,470 shares issued and outstanding as of December 31, 2011; 474,200,000 shares authorized and 157,417,702 shares issued and outstanding as of March 31, 2012)
Additional paid-in capital
Total shareholders' equity
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY
CONSOLIDATED RECONCILIATION OF NON-GAAP ADJUSTED NET INCOME
FOR THE QUARTERS ENDED MARCH 31, 2011 AND 2012
GAAP net income
Foreign exchange losses (gain)
Share-based compensation expenses
Fin 48 adjustment
Non-GAAP net income
CONTACT: China Nuokang Bio-Pharmaceutical Inc.
Mr. Steven Duan
Vice President of Investor Relations
Mr. Rob Koepp
Tel: (+86) 10-6583-7516 or (646) 405-5180